• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Real Labs, Actual Decisions With Actionable Six Sigma Metrics

    7/17/25 7:00:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $QDEL alert in real time by email

    QuidelOrtho Announces Featured ADLM Session

    SAN DIEGO, July 17, 2025 /PRNewswire/ -- How can actionable, Six Sigma insights improve lab performance? In a featured session at the Association for Diagnostics & Laboratory Medicine (ADLM) meeting, QuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho") and a panel of experts will share how QuidelOrtho's Six Sigma tools and real lab data can drive quality outcomes.

    Angela Armato, Core Lab Manager, United Health Services and UHS Hospitals

    ADLM Session Details:

    Session Title:

    Real Labs, Real Decisions with Actionable Six Sigma Metrics

    When:

    Tuesday, July 29, 2025

    Where:

    McCormick Convention Center

    Chicago, IL

    Exhibit Hall, Theater 1

    Time:

    2:45 p.m. – 3:45 p.m. CT

    Registration:

    Space is limited. ADLM attendees can register for the session using

    this link: https://www2.na-ma.quidelortho.com/25-adlm-workshop-subscribe

    Media registered for ADLM – please reach out to Nikki Wheeler to

    access the session at [email protected]



    Real Labs, Real Decisions With Actionable Six Sigma Metrics Panelists:

    Dr. Jared Jaeger

    Clinical Science Liaison

    QuidelOrtho

    Moderator

    Dr. Bremansu Osa-Andrews

    Medical Director of Clinical

    Chemistry and Clinical Assistant Professor

    University of Florida PathLab

    Gilles Attipoe

    Director of Laboratory Services

    St. Peter's University Hospital

    Angela Armato

    Core Lab Manager

    United Health Services and UHS Hospitals

    To learn more about Six Sigma and the value of using real-world data listen to "Sigma Metrics and the Value of Real World Evidence." In this podcast, QuidelOrtho data scientist Johanna Miller discusses how Six Sigma metrics are being adapted for the clinical laboratory.

    Unable to attend ADLM? Register to watch a recording of the session: https://www2.na-ma.quidelortho.com/25-adlm-workshop-subscribe.

    About QuidelOrtho

    QuidelOrtho Corporation (NASDAQ:QDEL) is a world leader in in vitro diagnostics, developing and manufacturing intelligent solutions that transform data into understanding and action for more people in more places every day.

    Offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, bringing fast, accurate and reliable diagnostics when and where they are needed–from home to hospital, lab to clinic.

    Building on its long history of innovation, QuidelOrtho works with global healthcare customers to advance diagnostics, where insights and solutions seamlessly connect, illuminating a clearer path for informed decisions.

    Investor Contact:

    Juliet Cunningham

    Vice President, Investor Relations

    [email protected]

    Media Contact:

    D. Nikki Wheeler

    Senior Director, Corporate Communications

    [email protected]

    Gilles Attipoe, Director of Laboratory Services, St. Peter's University Hospital

    Dr. Bremansu Osa-Andrews, Medical Director of Clinical Chemistry and Clinical Assistant Professor, University of Florida PathLab

    Dr. Jared Jaeger, Clinical Science Liaison, QuidelOrtho, Moderator

    QuidelOrtho Corporation (PRNewsfoto/QuidelOrtho Corporation)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/real-labs-actual-decisions-with-actionable-six-sigma-metrics-302507241.html

    SOURCE QuidelOrtho Corporation

    Get the next $QDEL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QDEL

    DatePrice TargetRatingAnalyst
    5/8/2025$44.00Hold → Buy
    Jefferies
    12/11/2024$44.00 → $50.00Neutral → Buy
    Citigroup
    12/10/2024$43.00Hold
    Jefferies
    9/19/2024$42.00 → $50.00Neutral
    UBS
    9/5/2024$40.00 → $57.00Hold → Buy
    Craig Hallum
    3/4/2024$70.00 → $42.00Neutral → Sell
    UBS
    2/14/2024$66.00 → $37.00Neutral → Underweight
    JP Morgan
    12/11/2023$95.00 → $72.00Buy → Neutral
    Citigroup
    More analyst ratings

    $QDEL
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by QuidelOrtho Corporation

    SCHEDULE 13G/A - QuidelOrtho Corp (0001906324) (Subject)

    8/7/25 3:58:39 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - QuidelOrtho Corp (0001906324) (Filer)

    8/5/25 4:11:59 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by QuidelOrtho Corporation

    SCHEDULE 13G/A - QuidelOrtho Corp (0001906324) (Subject)

    7/29/25 2:22:09 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    QuidelOrtho Welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development

    SAN DIEGO, Aug. 19, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development. In this role, Mr. Wolff will report directly to President and Chief Executive Officer Brian Blaser, and he will lead the Company's enterprise strategy, business development, government affairs and portfolio management functions. Mr. Wolff brings over two decades of leadership experience in strategy, M&A and business development across the heal

    8/19/25 4:05:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho Launches Certified Analyzer Program

    Initiative to expand testing access to underserved U.S. communities SAN DIEGO, Aug. 13, 2025 /PRNewswire/ -- QuidelOrtho Corporation has launched a Certified Analyzer Program, an innovative initiative designed to expand access to high-quality diagnostic testing in rural and community hospitals across the United States. Tailored for clinics, physician office labs and small hospitals with fewer than 100 beds, the program offers certified VITROS™ analyzers that deliver proven reliability and quality results, with award-winning service, at a fraction of the cost. "Our mission is r

    8/13/25 3:00:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho Reports Second Quarter 2025 Financial Results

    ― Labs revenue grew 4% as reported and 5% in constant currency ―― Adjusted EBITDA margin improved by 330 basis points; Achieved $100 million annualized cost savings from initiatives announced in 2024 ― ― Company reiterates full-year 2025 financial guidance ― Second Quarter 2025 Results(all comparisons are to the prior year period) Total revenue was $614 million, as reportedNon-respiratory revenue was $567 million, a decrease of 2% both as reported and in constant currency; excluding Donor Screening, non-respiratory revenue grew 1% in constant currencyLabs revenue grew 4% as reported and 5% in constant currencyImmunohematology revenue grew 4% as reported and 3% in constant currencyRespiratory

    8/5/25 4:10:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Blaser Brian J. bought $249,878 worth of shares (6,033 units at $41.42) (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    12/13/24 4:12:57 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Busky Joseph M bought $99,663 worth of shares (2,150 units at $46.35) (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    2/26/24 6:48:23 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Buechler Kenneth F exercised 9,215 shares at a strike of $15.74, increasing direct ownership by 10% to 101,921 units (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    7/17/25 4:09:04 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Legal Officer Hodges Michelle A was granted 11,873 shares and covered exercise/tax liability with 6,030 shares, increasing direct ownership by 25% to 29,212 units (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    7/2/25 4:10:58 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Financial Officer Busky Joseph M. was granted 21,367 shares and covered exercise/tax liability with 9,883 shares, increasing direct ownership by 58% to 31,427 units (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    7/2/25 4:08:51 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    QuidelOrtho upgraded by Jefferies with a new price target

    Jefferies upgraded QuidelOrtho from Hold to Buy and set a new price target of $44.00

    5/8/25 9:44:58 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho upgraded by Citigroup with a new price target

    Citigroup upgraded QuidelOrtho from Neutral to Buy and set a new price target of $50.00 from $44.00 previously

    12/11/24 8:21:07 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Jefferies initiated coverage on QuidelOrtho with a new price target

    Jefferies initiated coverage of QuidelOrtho with a rating of Hold and set a new price target of $43.00

    12/10/24 8:01:07 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    Financials

    Live finance-specific insights

    View All

    QuidelOrtho Reports Second Quarter 2025 Financial Results

    ― Labs revenue grew 4% as reported and 5% in constant currency ―― Adjusted EBITDA margin improved by 330 basis points; Achieved $100 million annualized cost savings from initiatives announced in 2024 ― ― Company reiterates full-year 2025 financial guidance ― Second Quarter 2025 Results(all comparisons are to the prior year period) Total revenue was $614 million, as reportedNon-respiratory revenue was $567 million, a decrease of 2% both as reported and in constant currency; excluding Donor Screening, non-respiratory revenue grew 1% in constant currencyLabs revenue grew 4% as reported and 5% in constant currencyImmunohematology revenue grew 4% as reported and 3% in constant currencyRespiratory

    8/5/25 4:10:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho to Report Second Quarter 2025 Financial Results

    SAN DIEGO, July 22, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its second quarter 2025 ended June 29, 2025, after the market close on Tuesday, August 5, 2025. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested

    7/22/25 4:30:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho Announces Strategy to Accelerate Growth in Molecular Diagnostics

    ―Company Intends to Acquire LEX Diagnostics Upon U.S. FDA Clearance――Company Plans to Discontinue Savanna® Platform Development――Company Reaffirms Full Year 2025 Financial Guidance ――Company to Host Conference Call Today at 5:00 p.m. ET― SAN DIEGO, June 3, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced a refocusing of its molecular diagnostics strategy. This strategy includes the intent to acquire full ownership of LEX Diagnostics after 510(k) clearance by the U.S. Food and Drug Administrat

    6/3/25 4:10:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation

    SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

    12/6/24 10:11:24 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13D/A filed by QuidelOrtho Corporation

    SC 13D/A - QuidelOrtho Corp (0001906324) (Subject)

    11/21/24 5:10:19 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation

    SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

    11/14/24 1:28:35 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    Leadership Updates

    Live Leadership Updates

    View All

    QuidelOrtho Welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development

    SAN DIEGO, Aug. 19, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development. In this role, Mr. Wolff will report directly to President and Chief Executive Officer Brian Blaser, and he will lead the Company's enterprise strategy, business development, government affairs and portfolio management functions. Mr. Wolff brings over two decades of leadership experience in strategy, M&A and business development across the heal

    8/19/25 4:05:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho Announces Appointment of Two Independent Directors to its Board

    Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

    12/10/24 7:00:00 AM ET
    $CTLT
    $HYPR
    $NVST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    QuidelOrtho Announces New R&D Executive Leader

    Jonathan Siegrist appointed as EVP of R&D and CTO QuidelOrtho Corporation (NASDAQ:QDEL), a global leader in innovative diagnostic solutions, is pleased to announce the appointment of Jonathan Siegrist, PhD, as its new Executive Vice President of Research and Development (R&D) and Chief Technology Officer (CTO), effective as of October 7, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241009251239/en/Jonathan Siegrist, EVP of R&D and CTO, QuidelOrtho (Photo: Business Wire) Siegrist brings a wealth of industry expertise and leadership experience with over 15 years in molecular diagnostics, microfluidic platforms, and biomedi

    10/9/24 7:00:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care